


IFW



I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: **MS Amendment**, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.  
Dated: May 25, 2004  
Signature: *Nabeela R. McMillian*  
Nabeela R. McMillian

Docket No.: 30610/39383  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of: *Zankel et al.*

Application No.: 10/600,862

Group Art Unit: Not Yet Assigned

Filed: June 20, 2003

Examiner: Not Yet Assigned

For: **USE OF CHAPERONE RECEPTOR-  
ASSOCIATED PROTEIN (RAP) FOR THE  
DELIVERY OF THERAPEUTIC  
COMPOUNDS TO THE BRAIN AND  
OTHER TISSUES**

**INFORMATION DISCLOSURE STATEMENT (IDS)**

**MS Amendment**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached Form PTO - 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

All patents and publications in the attached Form PTO - 1449 are supplied herewith, with the exception of the U.S. Patent Documents in accordance with the waiver of the requirement under 37 CFR 1.98 (a)(2)(i). The submission of this PTO-1449 and IDS is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for the instant application under any section of 35 U.S.C. §102 or 35 U.S.C. §103.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other



Application No.: 10/600,862

Docket No.: 30610/39383

material information as defined in 37 CFR 1.56(a) exists. It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

No additional fees are believed to be necessary, however, the Commissioner is hereby authorized to charge any deficiency in the fees filed or credit any overpayments to our Deposit Account No. 13-2855. A duplicate copy of this paper is enclosed.

Dated: May 25, 2004

Respectfully submitted,

By

Nabeela R. McMillian

Registration No.: 43,363

MARSHALL, GERSTEIN & BORUN LLP


233 S. Wacker Drive, Suite 6300

Sears Tower

Chicago, Illinois 60606-6357

(312) 474-6300

Attorney for Applicants



Form PTO-1449 (Modified)

U.S. Department of Commerce  
Patent and Trademark Office

Attorney Docket No.

30610/39383

Serial No.

10/600,862

## INFORMATION DISCLOSURE STATEMENT

Applicant

Zankel *et al.*

Filing Date

June 20, 2003

Group

Not Yet Assigned

## U.S. PATENT DOCUMENTS

*Examiner Initials		Document Number	Issue Date	Name	Class	Subclass	Filing Date if Appropriate
	A1	4,018,884	04/19/1977	Cleeland, Jr. <i>et al.</i>	436	547	
	A2	4,391,904	07/05/1983	Litman <i>et al.</i>	435	7.91	
	A3	4,394,448	07/19/1983	Szoka, Jr. <i>et al.</i>	435	458	
	A4	4,744,981	05/17/1988	Pavanasasivam	424	181.1	
	A5	4,897,255	01/30/1990	Fritzberg <i>et al.</i>	530	391.5	
	A6	4,988,496	01/29/1991	Srinivasan <i>et al.</i>	424	1.53	
	A7	5,106,951	04/21/1992	Morgan, Jr. <i>et al.</i>	530	391.9	
	A8	5,186,941	02/16/1993	Callahan <i>et al.</i>	424	450	
	A9	5,474,766	12/12/1995	Schwartz <i>et al.</i>	424	94.64	
	A10	5,962,012	10/05/1999	Lin <i>et al.</i>	424	448	
	A11	5,981,194	11/09/1999	Jeffries <i>et al.</i>	435	7.1	
	A12	6,261,595	07/17/2001	Stanley <i>et al.</i>	424	449	
	A13	6,447,775	09/10/2002	Strickland <i>et al.</i>	424	130.1	

## FOREIGN PATENT DOCUMENTS

*Examiner Initials		Document Number	Publication Date	Country	Class	Subclass	Translation	
	B1	WO 01/59459	08/16/2001	PCT			Yes	No
	B2	WO 02/13843	02/21/2002	PCT				

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

	C1	Altschul <i>et al.</i> , <i>J. Mol. Biol.</i> , <b>215(3)</b> :403-410 (1990)
	C2	Ashcom <i>et al.</i> , <i>J. Cell. Biol.</i> , <b>110(4)</b> :1041-1048 (1990)
	C3	Bickel <i>et al.</i> , <i>Adv. Drug Deliv. Rev.</i> , <b>46(1-3)</b> :247-279 (2001)
	C4	Blair <i>et al.</i> , <i>J. Immunol. Methods</i> , <b>59(2)</b> :129-143 (1983)
	C5	Blättler <i>et al.</i> , <i>Biochem.</i> , <b>24</b> :1517-1524 (1985)
	C6	Bu <i>et al.</i> , <i>J. Biol. Chem.</i> , <b>271(36)</b> :22218-2224 (1996)
	C7	Bu <i>et al.</i> , <i>Trends Cell. Biol.</i> , <b>8(7)</b> :272-276 (1998)
	C8	Czekay <i>et al.</i> , <i>Mol. Biol. Cell.</i> , <b>8(3)</b> :517-532 (1997)
	C9	Dehouck <i>et al.</i> , <i>J. Cell. Biol.</i> , <b>138(4)</b> :877-889 (1997)
	C10	Fahrlander <i>et al.</i> , <i>Bio/Technology</i> , <b>6</b> :1165-1168 (1988)
	C11	Feng <i>et al.</i> , <i>J. Mol. Evol.</i> , <b>25</b> :351-360 (1987)
	C12	Fillebeen <i>et al.</i> , <i>J. Biol. Chem.</i> , <b>274(11)</b> :7011-7017 (1999)
	C13	FitzGerald <i>et al.</i> , <i>J. Cell Biol.</i> , <b>129(6)</b> :1533-1541 (1995)
	C14	Genbank Accession No. AAH49517
	C15	Genbank Accession No. AAM90301
	C16	Genbank Accession No. CAA05085
	C17	Genbank Accession No. NP_506187
	C18	Genbank Accession No. NP_649950

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)

U.S. Department of Commerce  
Patent and Trademark Office

Attorney Docket No.

30610/39383

Serial No.

10/600,862

## INFORMATION DISCLOSURE STATEMENT

Applicant

Zankel *et al.*

Filing Date

June 20, 2003

Group

Not Yet Assigned

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

C19	Genbank Accession No. P30533
C20	Genbank Accession No. Q99068
C21	Genbank Accession No. X13916
C22	Genbank Accession No. XP_132029
C23	Genbank Accession No. XP_313261
C24	Gutierrez <i>et al.</i> , <i>J. Neuroimmunology</i> , <b>47(2)</b> :169-176 (1993)
C25	Henikoff <i>et al.</i> , <i>Proc. Natl. Acad. Sci. USA</i> , <b>89</b> :10915 (1989)
C26	Herz <i>et al.</i> , <i>Atherosclerosis</i> , <b>118 Suppl</b> :S37-S41 (1995)
C27	Herz <i>et al.</i> , <i>J. Biol. Chem.</i> , <b>266(32)</b> :21232-21238 (1991)
C28	Herz <i>et al.</i> , <i>J. Clin. Invest.</i> , <b>108(6)</b> :779-784 (2001)
C29	Higgins <i>et al.</i> , <i>Comput. Appl. Biosci.</i> , <b>5(2)</b> :151-153 (1989)
C30	Hoogerbrugge <i>et al.</i> , <i>Lancet</i> , <b>345(8962)</b> :1398-1402 (1995)
C31	Jensen <i>et al.</i> , <i>FEBS Lett.</i> , <b>255(2)</b> :275-280 (1989)
C32	Karlin <i>et al.</i> , <i>Proc. Natl. Acad. Sci. USA</i> , <b>90(12)</b> :5873-5877 (1993)
C33	Kilic <i>et al.</i> , <i>Stroke</i> , <b>34(5)</b> :1304-1310 (2003)
C34	King <i>et al.</i> , <i>Biochem.</i> , <b>25(19)</b> :5774-5779 (1986)
C35	Kushuhara <i>et al.</i> , <i>Drug Discov. Today</i> , <b>6(3)</b> :150-156 (2001)
C36	Lin <i>et al.</i> , <i>Science</i> , <b>260(5111)</b> :1130-1132 (1993)
C37	Medved <i>et al.</i> , <i>J. Biol. Chem.</i> , <b>274(2)</b> :717-727 (1999)
C38	Meilinger <i>et al.</i> , <i>FEBS Lett.</i> , <b>360(1)</b> :70-74 (1995)
C39	Melman <i>et al.</i> , <i>J. Biol. Chem.</i> , <b>276(31)</b> :29338-29346 (2001)
C40	Needleman <i>et al.</i> , <i>J. Mol. Biol.</i> , <b>48(3)</b> :443-453 (1970)
C41	Nielsen <i>et al.</i> , <i>Proc. Natl. Acad. Sci. USA</i> , <b>94(14)</b> :7521-7525 (1997)
C42	Orlando <i>et al.</i> , <i>Proc. Natl. Acad. Sci. USA</i> , <b>91(8)</b> :3161-3165 (1994)
C43	Pardridge, <i>J. Neurovirol.</i> , <b>5(6)</b> :556-569 (1999)
C44	Pearson <i>et al.</i> , <i>Proc. Natl. Acad. Sci. USA</i> , <b>85(8)</b> :2444-2448 (1988)
C45	Rall <i>et al.</i> , <i>J. Biol. Chem.</i> , <b>273(37)</b> :24152-24157 (1998)
C46	Savonen <i>et al.</i> , <i>J. Biol. Chem.</i> , <b>274(36)</b> :25877-25882 (1999)
C47	Smith <i>et al.</i> , <i>Adv. Appl. Math.</i> , <b>2</b> :482-489 (1981)
C48	Srinivasachar <i>et al.</i> , <i>Biochem.</i> , <b>28(6)</b> :2501-2509 (1989)
C49	SwissProt Primary Accession No. Q07954
C50	Takahashi <i>et al.</i> , <i>Proc. Natl. Acad. Sci. USA</i> , <b>89(19)</b> :9252-9256 (1992)
C51	Thompson <i>et al.</i> , <i>Nucleic Acids Res.</i> , <b>22(22)</b> :4673-4680 (1994)
C52	Tsuji <i>et al.</i> , <i>Adv. Drug Deliv. Rev.</i> , <b>36(2-3)</b> :277-290 (1999)
C53	Warshawsky <i>et al.</i> , <i>J. Biol. Chem.</i> , <b>269(5)</b> :3325-3330 (1994)
C54	Wilchek <i>et al.</i> , <i>Anal. Biochem.</i> , <b>171</b> :1-32 (1988)
C55	Williams <i>et al.</i> , <i>J. Biol. Chem.</i> , <b>267(13)</b> :9035-9040 (1992)
C56	Willnow <i>et al.</i> , <i>J. Biol. Chem.</i> , <b>267(36)</b> :26172-26180 (1992)
C57	Wisselaar <i>et al.</i> , <i>J. Biol. Chem.</i> , <b>268(3)</b> :2223-2231 (1993)
C58	Yenofsky <i>et al.</i> , <i>Proc. Natl. Acad. Sci. USA</i> , <b>87(9)</b> :3435-3439 (1990)

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.